In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Tetraphase (NASDAQ: TTPH), with a price target of $7. The company’s shares closed yesterday at $3.41.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.0% and a 43.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tetraphase with a $7 average price target, implying a 105.1% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $8 price target.
.
See today’s analyst top recommended stocks >>
Based on Tetraphase’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.54 million. In comparison, last year the company had a GAAP net loss of $31.81 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
